Last reviewed · How we verify
Ziltivekimab C
Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation and cardiovascular risk.
Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation and cardiovascular risk. Used for Reduction of cardiovascular risk in patients with coronary artery disease and elevated inflammatory markers.
At a glance
| Generic name | Ziltivekimab C |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | IL-6 inhibitor monoclonal antibody |
| Target | Interleukin-6 (IL-6) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Ziltivekimab binds to and neutralizes circulating interleukin-6, a key pro-inflammatory cytokine implicated in atherosclerosis and cardiovascular disease. By blocking IL-6, the drug aims to reduce systemic inflammation and lower the risk of major adverse cardiovascular events in patients with established coronary artery disease or at high cardiovascular risk.
Approved indications
- Reduction of cardiovascular risk in patients with coronary artery disease and elevated inflammatory markers
Common side effects
- Infection
- Injection site reactions
- Elevated liver enzymes
Key clinical trials
- A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab (PHASE1)
- ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ziltivekimab C CI brief — competitive landscape report
- Ziltivekimab C updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI